what the manufacturer is charging for its patented medicine in that country by their agents. This is called "parallel importing".
Parallel import (PI) has been used in several countries such as EU. In 1990, PI devoted perhaps two percent market share of the prescription drug market in the European Countries overall, with ranging from one percent in Germany to 5-10 percent in the Netherlands and eight percent in the UK.
Most of the EU countries have some requirements for parallel importing of medicinal products. For example imported product has to be granted a marketing authorization in the Member State of Origin, product is essentially similar to a product that has already received marketing authorization in the Member State of destination, importer has to have PI license, manufacture's authorization for the company responsible for re-labeling, re-packaging and re-call issued by the regulatory authority, batch control and batch testing and wholesalers authorization. Obviously parallel import has occurred in EU between European countries with approximately similar regulations and supportive agreement in this field.
There are some arguments about PI. Opponents of PI often claim that PI would support consumer deception and trade in counterfeit goods and pirated goods.
The benefits of parallel imports are: 1. Direct reduction in branded medicines price. 2. PI can be a complement to price control strategies. It provides health providers strong negotiating leverage with original manufacturers that they cut their prices down.
The costs of parallel imports are: 1. To the extent that original manufacturers set prices according to factors influencing market power, integrating markets through PI could raise the prices in exporting countries by reducing available medicines in supply chain. In this condition, firms could refuse to supply those markets.
2. Costs of transportation and repackaging in parallel trade may decrease a significant portion of any potential price advantages.
3. PI firms have no costs in R&D and marketing. They normally use marketing expenses of original manufacturers and their licensees, which could reduce their willingness to supply certain markets and products.
4. PI reduces profitability of original manufacturers. It can affect their R&D programs that are sensitive to such profit reductions and it can lead to slow down global drug development.
Parallel import is one of the policies that FDO adopt to cut the medicines price these days. It means that FDO allows the importers to (PI) some branded medicines. This policy has some pros and cons in Iran. Unfortunately, high amount of medicines that have been imported by importers (not agents) are coming from unregulated countries. It means that importers buy medicines from wholesalers in other countries that are not regulated from FDO's point of view. It makes us worried about safety, quality and efficacy of these medicines. PI in this shape won't be able to guarantee these requirements. It's possible to counterfeit medicines are parallel imported to the country via countries of beneficiary's unregulated market.
Counterfeit medicines are deliberately and fraudulently mislabeled with respect to identity and/or source. Counterfeiting can be relevant to both branded and generic medicines. Counterfeit medicines may include products with the correct ingredients but fake packaging, without active ingredients, with insufficient active ingredients or with the wrong ingredients. In 2003, the World Health Organization cited estimates that the annual earnings from substandard and/or counterfeit drugs were overUS$32 billion.
In addition because there is not enough supervision on route of transportation of medicines in PI (for example those which need cool chain for transportation), medicines might be corrupted and become out of use before their expiry date. Since branded owners don't accept the responsibility of parallel imported medicines in Iran, responsibility for adverse reactions of these medicines is unclear. In addition, according to mechanism of medicines supply in PI, sustainability in supply of paralleldistributed medicines is ambiguous. At last, current laboratories capacity in Iran is not enough to detect all kinds of substandard and counterfeiting medicines.
It's not logical to prioritize price and affordability over safety, quality and efficacy. FDO's supposed to find the most affordable medicines within those with acceptable safety, quality and efficacy. PI in Iran should have a role as supporting tool for imported medicines' supply, not the main tool.
There are two suggestions in order to reach to acceptable price in compare with reference price countries.
1. Negotiation with agents and branded owners in order to cut their medicines price down at the logical level in compare with reference price countries. It's obvious that small PI via trustable route can help to find real price level in other countries.
2. In all possible cases, 'me-too' medicines can act as a strong competitor to branded medicines. There are so many branded-generic medicines that have similar effect and indications with acceptable requirements. Formal importing of these medicines can push branded owners to cut their price down to maintain and support their market share. Totally, it seems PI in Iran has some advantages in the short-run but in the long-run, that's not guaranteed. 
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